Interestingly, the amplification of VEGF in tumours with high immune-ITH indicated a link to angiogenesis24 and anti-VEGFA combined with anti-PD-L1 ICB has been a successful phase III trial in advanced HCC (IMbrave150)5. Here, CD274 is linked to neoplasm.